Trial Profile
An Open-label, Single-arm, Phase II Study to Assess the Efficacy and Safety of Endostar (Recombinant Human Endostatin Injection) Plus Gemcitabine and Docetaxel in Treatment of Soft Tissue Sarcoma Patients With Pulmonary Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Docetaxel; Gemcitabine
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 21 Mar 2013 New trial record